Merck, Schering-Plough to Merge

Marino, Jonathan
March 2009
Mergers & Acquisitions Report;3/16/2009, Vol. 22 Issue 11, p17
The article reports on the merger of New Jersey-based pharmaceutical companies Merck and Schering-Plough in a cash and stock deal. The deal entails the payment of 10.50 dollars plus a half share of stock from Schering-Plough to Merck. The cash portion of the transaction consists of 9.8 billion dollars in cash plus 8.5 billion dollars in debt, with JP Morgan providing financing for the deal.


Related Articles

  • Merck, Schering-Plough Planning to Merge.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p3 

    The article reports on the merger plan of Merck & Co. Inc. and Schering-Plough Corp. It states that a future cash-and-stock deal between two giant companies is likely to happen considering the alleged adverse effects of economic woes of the U.S. on them. If completed, the merger is expected to...

  • Merck & Co. to Acquire Schering-Plough for $41 billion. Ramesh, Deepti // Chemical Week;3/16/2009, Vol. 171 Issue 8, p43 

    The article reports on the decision of Merck & Co. to acquire Schering-Plough. The deal, estimated at $41.1 billion in stock and cash, will create a megapharma company with combined sales of $47 billion. Under the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in...

  • Merck and Schering-Plough to merge.  // TCE: The Chemical Engineer;Apr2009, Issue 814, p5 

    The article deals with the decision of Merck & Co. to pay $41 billion to acquire pharmaceutical firm Schering-Plough. The boards of both companies have approved the offer, which is a 34 percent premium on the March 6, 2009 share price of Schering-Plough. An annual cost-savings of $3.5 billion is...

  • Merck's Fix: Schering-Plough for $41B. Martin, Scott // Red Herring;3/9/2009, p1 

    The article reports on the decision of pharmaceutical firm Merck to acquire Schering-Plough for $41 billion. The deal would benefit Merck as it promises to expand its position in the market. The deal, a $23.61 per share cash-and-stock transaction, was approved by Merck's board of directors at a...

  • More Big Pharma Consolidation; Merck, Schering-Plough to Merge. Boggs, Jennifer // BioWorld Today;3/10/2009, Vol. 20 Issue 45, p1 

    The article reports on the merger between Merck & Co. Inc. and Schering-Plough Corp. worth $41.1 billion in cash and stocks. The said merger is not in line with the strategy of Merck to focus growth on internal pipeline and in-licensing biotech products. ON the other hand, biotechnology...

  • Merck to close 3 sites in N.J., following high-profile merge. Daks, Martin C. // njbiz;5/3/2010, Vol. 23 Issue 18, p7 

    The article reports on the closure of three sites of Merck & Co. Inc. in New Jersey following its merger with Schering-Plough Corp. in 2009.

  • Chase Shares Rise on Optimism.  // American Banker;11/21/2002, Vol. 167 Issue 224, p20 

    Reports on the rise in J.P. Morgan Chase & Co.'s share prices as of November 21, 2002. Investors' speculation that its profits would recover as a cause for the rise; Comments by analysts; Decline in earnings since the merger with Chase Manhattan Corp.

  • Lehman Seeing Dimmer Prospects for JPM Chase. Reilly, Patrick; Rieker, Matthias // American Banker;3/21/2002, Vol. 167 Issue 55, p20 

    Reports on the lowering of forecast earnings for J.P. Morgan Chase and Co. stock by analyst Henry Dickson of Lehman Brothers in the U.S. Effects of underwriting and advising on mergers and acquisitions on the business; Implementation of stock rating system; Classification of stocks.

  • J.P. Morgan: Dimon effect paying off. Fredrickson, Tom // Crain's New York Business;10/2/2006, Vol. 22 Issue 40, p1 

    This article focuses on role of chief executive Jamie Dimon in the growth of JPMorgan Chase & Co. Dimon took charge of the company at the end of 2005 and the stock price of the bank has been rising since the news of his promotion broke out. J.P. Morgan's shares are increased by 43% since October...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics